Other OTC • Healthcare • Medical - Diagnostics & Research • US • USD
Interpace Biosciences, Inc. (IDXG) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 6 recommend buying, 1 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
